

Press Release

Toxikon Europe NV and SG Lab by Stevanato Group Announce a Strategic, Formal Partnership to Create a World-Class Scientific Service in Support of the Pharmaceutical and Biotech Industries.

March 14, 2017

Toxikon Europe NV and SG Lab - Stevanato Group laboratory focused on analytical chemistry, material properties, physical and mechanical performances - today announced the establishment of a formal, strategic partnership that will enable the two companies to leverage their collective expertise in premium container/closure development for small volume parenterals, the in-depth scientific knowledge and supporting cutting-edge analytical technologies. The intent of this partnership is to create and offer a suite of world-class supporting services which would allow Pharmaceutical and Biopharmaceutical companies to move much faster in the qualification and acceptance process of container and closure systems, which would shorten the "Time-to-Market" significantly. The support Toxikon Europe will give through this agreement pertains to extractable/leachable testing, toxicological assessments, impurity identifications and biocompatibility testing of container and closure systems or components thereof.

Piet Christiaens, Scientific Director, Toxikon Europe NV:

"I am extremely pleased that Stevanato Group and Toxikon Europe NV have taken this very important step forward in bundling their forces to provide to their customers an excellent service in container/closure qualification. From the initial discussions onwards, it was clear that both companies share the same values when it comes to service-oriented customer support. This partnership is therefore designed to help the pharmaceutical industry take full advantage of the supporting services and tap into the expertise and resources that will be offered through this cooperation. Through this strategic partnership, Toxikon Europe will be able to expand their position in the Asia Pacific Region, which is a vibrant, very important and rapidly developing market. In addition, it will allow us to expand our offerings in other parts of the globe, such as North- and South-America, while confirming our presence in the European market place."



Odra Pinato, SG Lab Analytics Coordinator, Stevanato Group:

“Thanks to this agreement, SG Lab can support pharmaceutical customers since the early stages of a new drug development. We help them in the selection of the best glass container including closure system, taking into account all the relevant aspects (compatibility, stability, quality). Combining skilled glass experts with Toxikon’s experienced scientists and cutting edge laboratory capabilities, we now can offer a comprehensive analytical service support”.

About Toxikon Europe NV:

Toxikon Europe is an independent, privately owned Contract Research Organisation, specialized in providing premium Extractable & Leachable Services to the Pharmaceutical Industry. Based in Belgium, Toxikon Europe supports Pharma Companies - across the Globe - in developing worldwide compliant (FDA, EMA) Testing Strategies to qualify Container/Closure Applications and Pharmaceutical Production Equipment from an Extractable & Leachable Perspective. In addition, the Toxikon group also provides Biocompatibility Testing Services (In-Vivo and In-Vitro testing) to both the Medical Device and the Pharmaceutical Industries.

Toxikon is ISO 17025 Accredited, GLP-Certified and GMP Accredited. Toxikon is also FDA registered.

Toxikon Europe N.V – Romeinsestraat 12 – B-3001 Leuven

www.toxikon.be – info@toxikon.be - + 32 16 40 04 84

About SG Lab

With a comprehensive expertise on research projects and science behind the primary packaging, SG Lab is the laboratory of Stevanato Group focused on analytical chemistry, material properties, physical and mechanical performances. With a skilled team of experts having the best-in-class expertise in primary packaging, it can help the customer understand the potential interactions between the pharmaceutical products and the containers.

Some examples of SG Lab scientific activity are: delamination propensity investigation, surfaces and silicone coating characterization (silicone layer coverage, thickness and distribution), container performances and drug-container interaction.

About Stevanato Group

Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines.

It comprises two operational divisions dedicated to serve the pharmaceutical industry: Pharmaceutical Systems with Ompi specialized in glass primary packaging and Balda, focused on specialty plastics and delivery devices; Engineering Systems with Spami, Optrel, InnoScan and SVM, specialized in glass processing, inspection systems, assembly and packaging solutions.

www.stevanatogroup.com

